Fig. 7. AMPK is involved in TLR3 ligand, Poly (I:C)-induced YAP1 activation and neonatal cardiomyocyte proliferation.

a Treatment of neonatal cardiomyocytes with Poly (I:C) significantly decreased the levels of phosphorylated AMPK in neonatal cardiomyocytes. b Inhibition of glycolysis by 2-DG increased AMPK phosphorylation and abolished Poly (I:C) induced decreases in the levels of dephosphorylated AMPK. c, d Treatment of neonatal cardiomyocytes with an  AMPK activator, metformin, prevents Poly (I:C) induced dephosphorylation of AMPK c and YAP1 d. e, f Treatment of neonatal cardiomyocytes with the AMPK activator metformin prevented Poly (I:C) induced YAP1 nuclear translocation e and neonatal cardiomyocyte proliferation f. n = 3–6/group. *p < 0.05 compared with indicated groups. ^#p < 0.05 compared with the control group